Cullen/Frost Bankers’s Veracyte VCYT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$46.6K Buy
794
+74
+10% +$3.1K ﹤0.01% 881
2026
Q1
$23.2K Buy
720
+33
+5% +$1.22K ﹤0.01% 958
2025
Q4
$28.9K Buy
687
+103
+18% +$4.15K ﹤0.01% 914
2025
Q3
$20K Buy
584
+10
+2% +$287 ﹤0.01% 944
2025
Q2
$15.5K Buy
574
+397
+224% +$11.5K ﹤0.01% 961
2025
Q1
$5.25K Buy
177
+33
+23% +$1.26K ﹤0.01% 1034
2024
Q4
$5.7K Buy
144
+23
+19% +$871 ﹤0.01% 977
2024
Q3
$4.12K Buy
+121
New +$3.4K ﹤0.01% 1028

Other funds holding VCYT

Cullen/Frost Bankers's VCYT Position: Q2 2026 in Review

Cullen/Frost Bankers increased its Veracyte (VCYT) stake by 10% in Q2 2026, buying an estimated $3.1K and bringing the position to 794 shares worth $46.6K. The position accounts for ﹤0.01% of the portfolio, ranked #881.

Cullen/Frost Bankers first reported a position in VCYT in Q3 2024 and has held it in 8 quarters since. 166 funds tracked by Wall St. Rank hold VCYT as of Q2 2026.

  • Cullen/Frost Bankers held 794 shares of Veracyte worth $46.6K as of Q2 2026.
  • Cullen/Frost Bankers bought 74 Veracyte shares in Q2 2026, an estimated $3.1K.
  • Veracyte made up ﹤0.01% of Cullen/Frost Bankers's portfolio in Q2 2026, its #881 holding.
  • Cullen/Frost Bankers first reported a position in Veracyte in Q3 2024 and has held it in 8 quarters since.
  • 166 funds tracked by Wall St. Rank held Veracyte as of Q2 2026.

Based on Cullen/Frost Bankers's 13F filing for Q2 2026, filed 27 Jul 2026.